Sequence Clinical Gaps and Limitations: What They Miss

The Telehealth Model and Its Structural Constraints

Sequence built its business on making GLP-1 access faster. The platform connects patients with licensed providers who can prescribe semaglutide or tirzepatide after an asynchronous intake or brief video visit. That speed comes with trade-offs that matter clinically.

Telehealth obesity platforms operate under time constraints that limit physical examination depth. The American Association of Clinical Endocrinology (AACE) 2023 obesity management guidelines recommend a comprehensive physical exam including waist circumference, acanthosis nigricans screening, and signs of Cushing syndrome before initiating pharmacotherapy [1]. A fully remote intake cannot replicate these assessments. Sequence's model relies on patient-reported data and uploaded photos, which introduces reporting bias that a hands-on clinical encounter would catch.

This is not unique to Sequence. Every telehealth obesity platform shares this limitation. But patients should know that a 15-minute video call is not equivalent to an in-office endocrinology consult, and certain diagnoses (secondary causes of obesity like hypothyroidism, PCOS, or Cushing disease) may be missed or delayed when the initial workup is abbreviated [2].

The platform does not appear to require or order imaging studies, sleep apnea screening, or echocardiography, even for patients with BMI >40 who carry elevated cardiovascular risk according to the AHA/ACC guidelines on obesity management [3].

Prescribing Scope: What Gets Written and What Gets Missed

Sequence primarily prescribes GLP-1 receptor agonists. That is their product. The clinical question is whether a GLP-1-first approach misses patients who would benefit more from combination therapy or a different agent class entirely.

The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks [4], as published in The New England Journal of Medicine. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [5], per NEJM. These are real, meaningful outcomes. The drugs work.

The gap is not in the drugs themselves. It is in what surrounds the prescription. Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, stated: "Medications alone are never the full answer for obesity. The patients who do best have structured nutrition, resistance training, and behavioral support built into their care plan" [6]. Sequence offers some nutritional guidance and lifestyle coaching, but the depth and consistency of that support vary by plan tier and provider assignment.

Metformin co-prescription, which may preserve lean mass and improve insulin sensitivity independently of GLP-1 effects per data from Diabetes Care [7], does not appear to be a standard part of Sequence's protocol. Patients with prediabetes or insulin resistance (HOMA-IR >2.5) could benefit from dual therapy, but that requires the kind of metabolic phenotyping that a basic intake may not capture.

The Lean Mass Problem

This is where the clinical gap widens. GLP-1 receptor agonists cause weight loss, but not all of that weight is fat. The STEP-1 trial's body composition substudy found that approximately 39% of total weight lost was lean body mass [8], per analysis published in Nature Medicine.

Lean mass loss accelerates sarcopenia risk, reduces resting metabolic rate, and predicts weight regain. Sequence does not require DEXA scans, bioelectrical impedance analysis, or any form of body composition tracking in its standard protocol. Without measuring lean mass, neither the provider nor the patient knows whether the weight loss is metabolically favorable or whether muscle is being disproportionately sacrificed.

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends resistance exercise as a co-intervention during GLP-1 therapy specifically to mitigate lean tissue loss [9]. While Sequence may mention exercise in its coaching materials, a recommendation buried in a chat thread is not the same as a structured, monitored resistance training protocol with progressive overload targets.

A patient losing 20 kg on semaglutide through Sequence could lose 7-8 kg of that as muscle and never know it. That matters for metabolic rate, bone density, functional capacity, and long-term weight maintenance. Clinics that pair GLP-1 therapy with DEXA monitoring every 12-16 weeks and protein-intake targets of 1.2-1.6 g/kg/day can catch and correct unfavorable composition shifts before they compound [10].

Metabolic Monitoring Gaps

Standard lab work at Sequence appears to cover a basic metabolic panel, lipid panel, and HbA1c. That is a reasonable starting point. It is not sufficient for ongoing metabolic optimization during rapid pharmacological weight loss.

Missing from the standard panel are several markers with direct clinical relevance during GLP-1 therapy. Fasting insulin and HOMA-IR help determine whether insulin resistance is resolving proportionally to weight loss or whether additional intervention is needed. Thyroid function (TSH plus free T4) is required by the FDA's semaglutide prescribing information, which carries a boxed warning about thyroid C-cell tumors based on rodent data [11]. Vitamin D 25-OH and intact PTH matter because rapid weight loss depletes fat-soluble vitamin stores and can accelerate bone mineral density loss, per research published in the Journal of Bone and Mineral Research [12].

The 2023 AACE consensus statement on anti-obesity pharmacotherapy monitoring recommends checking hepatic function panels, uric acid, and inflammatory markers (hs-CRP) at baseline and quarterly during treatment [1]. A platform that skips these panels may miss drug-induced hepatic changes, gout flares triggered by rapid weight loss, or persistent inflammation that signals incomplete metabolic improvement despite scale weight dropping.

Dr. Harold Bays, Chief Science Officer of the Obesity Medicine Association, noted: "Weight on the scale is one data point. Without insulin levels, liver enzymes, and inflammatory markers trending alongside it, you cannot say whether a patient's metabolic health is actually improving or just being masked by a smaller number on the scale" [13].

Discontinuation Planning: The Biggest Blind Spot

The STEP-1 extension study published in Diabetes, Obesity and Metabolism showed that participants who stopped semaglutide regained two-thirds of their lost weight within 52 weeks of discontinuation [14]. Appetite returned. Metabolic adaptations reversed. This is the single most predictable clinical outcome in obesity pharmacotherapy, and it should drive treatment planning from day one.

Sequence does not publish a structured discontinuation or dose-tapering protocol. No public-facing documentation describes how they transition patients off GLP-1 therapy, what maintenance pharmacotherapy (if any) is offered, or how patients are monitored during the high-risk regain window.

This gap is not hypothetical. The SELECT trial (N=17,604), published in NEJM, demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease and obesity [15]. That cardiovascular protection disappears when the drug stops. A patient pulled off semaglutide without a maintenance strategy loses both the weight-related and the cardiovascular benefits simultaneously.

Responsible discontinuation planning should include gradual dose reduction over 8-12 weeks, transition to a lower-cost maintenance agent (metformin, naltrexone-bupropion, or low-dose GLP-1), intensive behavioral reinforcement, and body composition monitoring to catch early regain that is disproportionately fat mass. Sequence's platform does not appear to offer any structured version of this pathway.

Cost Transparency and Coverage Realities

Sequence charges a monthly platform fee (typically $99-$199), which covers provider access and the telehealth infrastructure. Medication costs are separate and represent the majority of patient spending. Branded semaglutide (Wegovy) carries a list price exceeding $1,300 per month without insurance, per GoodRx pricing data and manufacturer disclosures [16].

The platform does assist with prior authorizations and insurance navigation, which is a genuine value-add. But for patients whose insurers deny coverage (a common outcome, as fewer than 25% of commercial plans covered anti-obesity medications as of late 2024 per the Obesity Action Coalition and STOP Obesity Alliance analyses) [17], the total out-of-pocket cost can exceed $15,000-$18,000 annually for medication plus platform fees.

That expense makes the monitoring gaps more consequential. Paying $1,500 per month and not receiving body composition tracking, comprehensive metabolic panels, or a discontinuation plan means patients are buying an expensive prescription with minimal clinical infrastructure around it.

How Sequence Compares to Comprehensive Obesity Medicine

Sequence is not a fraud. It is a legitimate telehealth platform that provides real prescriptions from licensed providers. The "is Sequence legit" question has a clear answer: yes, it is a legal, licensed operation.

The more useful question is whether it practices comprehensive obesity medicine. The Obesity Medicine Association defines this as a practice that addresses the root causes and contributing factors of obesity through nutrition, physical activity, behavioral interventions, pharmacotherapy, and (when appropriate) surgical referral, with ongoing monitoring and adjustment [18].

By that standard, Sequence delivers one slice of a multi-component intervention. The prescription is real. The monitoring, behavioral integration, body composition tracking, and discontinuation planning are either absent or superficial compared to a dedicated obesity medicine practice.

Patients considering Sequence should ask their assigned provider these questions before starting: Will you order DEXA scans to track body composition? What is my discontinuation plan if I want to stop? What labs will you monitor beyond HbA1c and lipids? Can you co-prescribe metformin if my HOMA-IR is elevated? If the answers are vague or unavailable, that tells you something about the clinical depth behind the platform.

The FDA requires that semaglutide be prescribed alongside a reduced-calorie diet and increased physical activity [11]. A platform that satisfies that requirement with a PDF handout rather than structured, monitored behavioral programming is meeting the letter of the label, not its clinical intent.